Amy­lyx snatched the land­mark ap­proval for its ALS drug. Now it’s seek­ing cash to foot the launch bill

As Amy­lyx gets ready to de­but its ALS drug in the US — amid scruti­ny and crit­i­cism of the price it’s set — the biotech is go­ing back to the pub­lic mar­ket for some cash to fund the com­mer­cial work.

The of­fer­ing of six mil­lion shares is ex­pect­ed to fetch Amy­lyx any­where from $167 mil­lion to $192.2 mil­lion, de­pend­ing on the fi­nal price and whether un­der­writ­ers ex­er­cise their op­tion to buy more shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER